CLINICAL_TRIALS
trial_result
· 2017-09-27
Clinical Trial Update: Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia [Phase 2]
Summary
Phase 2 trial evaluated efficacy and safety of GSK239512 in schizophrenia. The study is completed and results were posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: GlaxoSmithKline | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2017-09-27